NCR3LG1 and neoplasm: Previous studies have demonstrated that PDL1, B7H3, B7H6 blockade enhance naïve T cell priming in draining lymph nodes, reactivating dysfunctional T cells in tumor tissues, or by increasing antitumor response (52–55).